

# Jun Yong Park

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633575/publications.pdf>

Version: 2024-02-01

370  
papers

10,743  
citations

36203

51  
h-index

62479

80  
g-index

386  
all docs

386  
docs citations

386  
times ranked

10411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). <i>Hepatology</i> , 2011, 53, 885-894.	3.6	329
2	Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). <i>Hepatology</i> , 2016, 63, 776-786.	3.6	261
3	Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e44930.	1.1	242
4	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. <i>Liver International</i> , 2010, 30, 546-553.	1.9	225
5	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1382-1390.	0.2	194
6	Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. <i>Hepatology</i> , 2014, 60, 954-963.	3.6	169
7	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	1.8	148
8	Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. <i>Liver International</i> , 2014, 34, 102-109.	1.9	143
9	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean. <i>PLoS ONE</i> , 2012, 7, e39175.	1.1	137
10	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	1.8	131
11	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763.	1.1	122
12	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	3.6	121
13	Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. <i>Hepatology</i> , 2011, 53, 1486-1493.	3.6	120
14	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.2	120
15	MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. <i>Carcinogenesis</i> , 2008, 29, 1192-1196.	1.3	119
16	Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2008, 28, 393-401.	1.9	113
17	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 415-421.	3.6	107
18	Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2007, 110, 129-137.	2.0	102

#	ARTICLE	IF	CITATIONS
19	Serotonin signals through a gut-liver axis to regulate hepatic steatosis. <i>Nature Communications</i> , 2018, 9, 4824.	5.8	98
20	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	3.6	97
21	Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 969-976.	1.9	96
22	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71.	1.1	94
23	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	1.9	91
24	Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1682-1691.	1.1	90
25	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478.	1.1	88
26	Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. <i>Journal of Hepatology</i> , 2018, 68, 764-772.	1.8	86
27	Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2012, 7, e36676.	1.1	84
28	Outcome after curative resection for a huge (≥10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. <i>American Journal of Surgery</i> , 2009, 198, 693-701.	0.9	82
29	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839.	2.3	78
30	Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study. <i>Hepatology International</i> , 2008, 2, 471-7.	1.9	77
31	What are "true normal" liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274.	1.9	76
32	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	1.9	76
33	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	1.3	71
34	Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®). <i>Annals of Surgical Oncology</i> , 2012, 19, 4278-4286.	0.7	70
35	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68
36	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.2	68

#	ARTICLE	IF	CITATIONS
37	Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1377-1384.	1.2	67
38	Liver Stiffness Measurement in Combination With Noninvasive Markers for the Improved Diagnosis of B-viral Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 267-271.	1.1	66
39	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 411-429.	4.5	66
40	Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 235-241.	0.6	64
41	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	1.9	64
42	Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964.	1.1	64
43	Prognostic value of $\alpha$ -fetoprotein and des- $\gamma$ -carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>BMC Cancer</i> , 2013, 13, 5.	1.1	60
44	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575.	1.3	59
45	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 659-667.	1.2	57
46	Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1384-1390.	1.4	57
47	Prognostic value of $^{18}\text{F}$ -FDG PET for hepatocellular carcinoma patients treated with sorafenib. <i>Liver International</i> , 2011, 31, 1144-1149.	1.9	56
48	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.2	56
49	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 373-382.	1.1	55
50	Early $\alpha$ -fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 369-376.	1.9	55
51	Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 130-136.	1.4	53
52	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	0.7	53
53	Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	52
54	Liver stiffness measurement using FibroScan <sup>®</sup> is influenced by serum total bilirubin in acute hepatitis. <i>Liver International</i> , 2009, 29, 810-815.	1.9	51

#	ARTICLE	IF	CITATIONS
55	Characterization of focal liver masses using acoustic radiation force impulse elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 219.	1.4	51
56	Clinical Features and Prognosis of Spontaneous Bacterial Peritonitis in Korean Patients with Liver Cirrhosis: A Multicenter Retrospective Study. <i>Gut and Liver</i> , 2009, 3, 197-204.	1.4	51
57	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2009, 81, 1002-1008.	2.5	50
58	The Accuracy of Noninvasive Methods in Predicting the Development of Hepatocellular Carcinoma and Hepatic Decompensation in Patients With Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 518-525.	1.1	49
59	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162.	0.4	49
60	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
61	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158.	1.4	48
62	<sup>18</sup> F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	2.0	47
63	Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2010, 82, 1835-1842.	2.5	46
64	Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825.	1.1	45
65	Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1008-1017.	1.9	44
66	Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. <i>Journal of Hepatology</i> , 2019, 71, 289-300.	1.8	44
67	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020, 40, 1032-1041.	1.9	44
68	Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 485-493.	1.9	43
69	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	1.9	43
70	Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. <i>Hepatology International</i> , 2010, 4, 673-680.	1.9	42
71	Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.4	42
72	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544.	1.1	42

#	ARTICLE	IF	CITATIONS
73	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	0.8	42
74	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891.	0.2	42
75	Hepatocellular carcinoma in Budd-Chiari syndrome: A single center experience with long-term follow-up in South Korea. <i>World Journal of Gastroenterology</i> , 2012, 18, 1946.	1.4	42
76	Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. <i>Immune Network</i> , 2020, 20, e11.	1.6	42
77	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , 2012, 13, 47.	2.1	40
78	Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2 $\beta$ activity in healthy and pathologic livers. <i>Journal of Hepatology</i> , 2020, 72, 1170-1181.	1.8	39
79	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	3.2	38
80	Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. <i>Gut</i> , 2015, 64, 1303-1313.	6.1	38
81	Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: Culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 122-128.	1.4	37
82	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919.	3.6	37
83	Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	1.9	37
84	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887.	1.9	37
85	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229.	1.4	37
86	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	1.7	37
87	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
88	Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1722-1727.	1.4	36
89	Role of surgical resection for multiple hepatocellular carcinomas. <i>World Journal of Gastroenterology</i> , 2013, 19, 366.	1.4	36
90	Impact of Spontaneous Hepatocellular Carcinoma Rupture on Recurrence Pattern and Long-term Surgical Outcomes after Partial Hepatectomy. <i>World Journal of Surgery</i> , 2014, 38, 2070-2078.	0.8	36

#	ARTICLE	IF	CITATIONS
91	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	1.4	36
92	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856.	0.8	35
93	Combined measurement of preoperative Î±-fetoprotein and des-Î³-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 2332-2341.	2.3	35
94	Human liver CD8+ MAIT cells exert TCR/MR1-independent innate-like cytotoxicity in response to IL-15. <i>Journal of Hepatology</i> , 2020, 73, 640-650.	1.8	35
95	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	1.9	34
96	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	1.1	34
97	Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study. <i>Liver International</i> , 2008, 28, 1389-1395.	1.9	33
98	Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 165-173.	1.1	33
99	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296.	0.9	33
100	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	1.1	33
101	Efficacy and Safety of Transarterial Chemoembolization in Recurrent Hepatocellular Carcinoma After Curative Surgical Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 564-569.	0.6	32
102	Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. <i>Liver International</i> , 2012, 32, 796-802.	1.9	32
103	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	1.9	32
104	A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009.	1.1	32
105	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6.	2.4	32
106	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39.	0.8	32
107	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , 2010, 30, 1073-1081.	1.9	31
108	The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. <i>Yonsei Medical Journal</i> , 2016, 57, 885.	0.9	31

#	ARTICLE	IF	CITATIONS
109	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	4.5	31
110	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	4.5	31
111	Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322.	1.4	30
112	Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 722-729.	0.4	30
113	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	1.1	30
114	Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788.	1.4	29
115	Red cell volume distribution width to platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 24-30.	1.9	29
116	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	1.9	29
117	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189.	1.9	28
118	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542.	1.4	28
119	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328.	0.4	28
120	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	2.9	28
121	Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea. <i>Yonsei Medical Journal</i> , 2011, 52, 753.	0.9	27
122	Inhibition of tumour angiogenesis and growth by small hairpin <i>h</i> HIF1 $\alpha$ and <i>h</i> IL8 in hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 632-642.	1.9	27
123	Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. <i>Yonsei Medical Journal</i> , 2018, 59, 452.	0.9	27
124	Association between IL28B Polymorphisms and Spontaneous Clearance of Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2013, 8, e69166.	1.1	26
125	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	1.4	26
126	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	1.7	26



#	ARTICLE	IF	CITATIONS
127	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268.		26
128	Efficacy of Lenervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3043-3045.e1.	2.4	26
129	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55.	1.0	26
130	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. <i>Antiviral Therapy</i> , 2009, 14, 705-712.	0.6	26
131	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 517-526.	1.2	25
132	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884.	1.1	25
133	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. <i>PLoS ONE</i> , 2015, 10, e0139227.	1.1	25
134	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	1.3	25
135	Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. <i>PLoS ONE</i> , 2014, 9, e99167.	1.1	24
136	Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 272-278.	1.1	24
137	Early $\alpha$ -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 39.	1.8	24
138	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 828-834.	1.4	24
139	Additional fibrate treatment in UDCA-refractory PBC patients. <i>Liver International</i> , 2019, 39, 1776-1785.	1.9	24
140	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1.	2.4	24
141	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. <i>PLoS ONE</i> , 2017, 12, e0187066.	1.1	24
142	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , 2017, 11, 268-276.	1.9	23
143	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. <i>Liver International</i> , 2020, 40, 1736-1743.	1.9	23
144	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. <i>OncoTargets and Therapy</i> , 2013, 6, 1463.	1.0	22

#	ARTICLE	IF	CITATIONS
145	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for&nbsp;hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 347.	1.0	22
146	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	1.9	22
147	Tumor Necrosis Factor-producing T-regulatory Cells Are Associated With Severe Liver Injury in Patients With Acute Hepatitis A. <i>Gastroenterology</i> , 2018, 154, 1047-1060.	0.6	22
148	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	1.9	22
149	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325.	1.4	22
150	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	1.4	22
151	YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. <i>Hepatology</i> , 2021, 74, 2605-2621.	3.6	22
152	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984.	0.8	22
153	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847.	1.4	21
154	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527.	1.7	21
155	Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	0.6	20
156	Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 184-191.	0.9	20
157	Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. <i>Digestion</i> , 2012, 85, 219-227.	1.2	20
158	<sup>18</sup> F-FDG PET Metabolic Parameters and MRI Perfusion and Diffusion Parameters in Hepatocellular Carcinoma: A Preliminary Study. <i>PLoS ONE</i> , 2013, 8, e71571.	1.1	20
159	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	1.1	20
160	Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years. <i>World Journal of Surgical Oncology</i> , 2014, 12, 192.	0.8	20
161	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. <i>Liver International</i> , 2016, 36, 1108-1115.	1.9	20
162	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	1.6	20

#	ARTICLE	IF	CITATIONS
163	Early reduction of regulatory T cells is associated with acute rejection in liver transplantation under tacrolimus-based immunosuppression with basiliximab induction. <i>American Journal of Transplantation</i> , 2020, 20, 2058-2069.	2.6	20
164	Serum <i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 33-44.	4.5	20
165	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	4.5	20
166	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774.	1.4	20
167	Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. <i>Journal of Medical Virology</i> , 2009, 81, 594-601.	2.5	19
168	Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , 2009, 29, 760-766.	1.9	19
169	Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment. <i>PLoS ONE</i> , 2013, 8, e52720.	1.1	19
170	Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 286-292.	1.9	19
171	Knockdown of HIF-1 $\alpha$ and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 85-95.	2.2	19
172	Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 910-917.	1.4	19
173	Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea. <i>Annals of Surgical Treatment and Research</i> , 2019, 96, 275.	0.4	19
174	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115.	0.4	19
175	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	4.5	19
176	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635.	1.4	19
177	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , 2015, 35, 455-462.	1.9	18
178	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18
179	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1079-1086.	1.4	18
180	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18

#	ARTICLE	IF	CITATIONS
181	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	0.8	18
182	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092.	1.9	18
183	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	2.4	17
184	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	1.3	17
185	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77.	0.9	17
186	Dynamics of the Liver Stiffness Value Using Transient Elastography during the Perioperative Period in Patients with Valvular Heart Disease. <i>PLoS ONE</i> , 2014, 9, e92795.	1.1	17
187	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275.	1.4	17
188	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , 2010, 30, 860-866.	1.9	16
189	How Many Valid Measurements Are Necessary to Assess Liver Fibrosis Using FibroScan® in Patients with Chronic Viral Hepatitis? An Analysis of Subjects with at Least 10 Valid Measurements. <i>Yonsei Medical Journal</i> , 2012, 53, 337.	0.9	16
190	Antibody-Secreting Cells with a Phenotype of Ki-67low, CD138high, CD31high, and CD38high Secrete Nonspecific IgM during Primary Hepatitis A Virus Infection. <i>Journal of Immunology</i> , 2013, 191, 127-134.	0.4	16
191	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011.	1.4	16
192	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	1.9	16
193	Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. <i>Scientific Reports</i> , 2018, 8, 15629.	1.6	16
194	Cutaneous Metastasis from Cholangiocarcinoma as the First Clinical Sign: A Report of Two Cases. <i>Gut and Liver</i> , 2011, 5, 100-104.	1.4	16
195	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36.	1.4	16
196	Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study. <i>Magnetic Resonance Imaging</i> , 2010, 28, 802-811.	1.0	15
197	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 882.	1.1	15
198	Optimal Time for Restoring the Reliability of Liver Stiffness Measurement in Patients With Chronic Hepatitis B Experiencing Acute Exacerbation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 602-607.	1.1	15

#	ARTICLE	IF	CITATIONS
199	Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. <i>Cancer Cell International</i> , 2017, 17, 3.	1.8	15
200	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.4	15
201	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.2	15
202	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	1.9	15
203	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578.	1.0	15
204	Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. <i>Journal of Liver Cancer</i> , 2020, 20, 41-52.	0.3	15
205	Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. <i>Journal of Liver Cancer</i> , 2020, 20, 135-147.	0.3	15
206	Chemotherapy for advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 682-684.	1.4	14
207	Normal enhanced liver fibrosis (<sc>ELF</sc>) values in apparently healthy subjects undergoing a health checkup and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713.	1.9	14
208	Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242.	1.1	14
209	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434.	0.4	14
210	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624.	0.6	14
211	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	0.8	14
212	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	1.4	14
213	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534.	1.4	13
214	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	0.6	13
215	Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. <i>BMC Gastroenterology</i> , 2019, 19, 90.	0.8	13
216	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	1.0	13

#	ARTICLE	IF	CITATIONS
217	Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 249-258.	1.9	13
218	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	1.3	13
219	Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 976-986.e5.	2.4	13
220	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 29.	4.5	13
221	A 96-Week Randomized Trial of Switching to Entecavir in Chronic Hepatitis B Patients with a Partial Virological Response to Lamivudine. <i>Antiviral Therapy</i> , 2012, 17, 1563-1570.	0.6	12
222	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1348-1355.e2.	2.4	12
223	Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807.	2.4	12
224	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	1.4	12
225	Effects of the knockdown of hypoxia inducible factor-1 $\alpha$ expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. <i>The Korean Journal of Hepatology</i> , 2010, 16, 280.	1.5	12
226	Spontaneous rupture of hepatic metastasis from a thymoma: A case report. <i>World Journal of Gastroenterology</i> , 2016, 22, 9860.	1.4	12
227	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	1.4	12
228	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	1.4	12
229	What is the role of diagnostic laparoscopy in a gastroenterology unit?. <i>Journal of Gastroenterology</i> , 2007, 42, 881-886.	2.3	11
230	Combination of preS Deletions and A1762T/G1764A Mutations in HBV Subgenotype C2 Increases the Risk of Developing HCC. <i>Intervirology</i> , 2012, 55, 112-118.	1.2	11
231	Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 499-506.	0.6	11
232	Acute Variceal Hemorrhage in Patients with Liver Cirrhosis: Weekend versus Weekday Admissions. <i>Yonsei Medical Journal</i> , 2012, 53, 318.	0.9	11
233	Spontaneous Bacterial Peritonitis in Patients with Hepatitis B Virus-Related Liver Cirrhosis: Community-Acquired versus Nosocomial. <i>Yonsei Medical Journal</i> , 2012, 53, 328.	0.9	11
234	Prevention and Management of Variceal Hemorrhage. <i>International Journal of Hepatology</i> , 2013, 2013, 1-6.	0.4	11

#	ARTICLE	IF	CITATIONS
235	Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 755.	1.0	11
236	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65.	0.8	11
237	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
238	Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759.	1.1	11
239	Silencing of Hypoxia-Inducible Factor-1 $\beta$ Induces Anti-Tumor Effects in Hepatoma Cell Lines under Tumor Hypoxia. <i>PLoS ONE</i> , 2014, 9, e103304.	1.1	11
240	A Case of Embryonal Sarcoma of the Liver Mimicking a Hydatid Cyst in an Adult. <i>Gut and Liver</i> , 2010, 4, 245-249.	1.4	11
241	Synchronous development of intrahepatic cholangiocarcinoma and hepatocellular carcinoma in different sites of the liver with chronic B-viral hepatitis: two case reports. <i>BMC Research Notes</i> , 2013, 6, 520.	0.6	10
242	Maintaining remission in lamivudine-resistant patients with a virological response to adefovir after lamivudine after stopping lamivudine therapy. <i>Liver International</i> , 2014, 34, 1543-1549.	1.9	10
243	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261.	4.5	10
244	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016, 22, 443-449.	4.5	10
245	Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. <i>Scientific Reports</i> , 2022, 12, 193.	1.6	10
246	Clinical Features of Re-Emerging Hepatitis A: An Analysis of Patients Hospitalized during an Urban Epidemic in Korea. <i>Yonsei Medical Journal</i> , 2011, 52, 686.	0.9	9
247	Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2811-2813.e1.	2.4	9
248	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	1.0	9
249	Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414.	1.7	9
250	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	1.2	9
251	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	1.3	9
252	Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 251.	4.5	9

#	ARTICLE	IF	CITATIONS
253	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2015, 9, 776.	1.4	9
254	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirology</i> , 2008, 51, 293-298.	1.2	8
255	Clinical features and prognosis of hepatocellular carcinoma with respect to pre- $\epsilon$ deletion and basal core promoter mutations of hepatitis B virus Genotype C2. <i>Journal of Medical Virology</i> , 2011, 83, 2088-2095.	2.5	8
256	Lamivudine plus adefovir vs. entecavir in $\langle \text{sc} \rangle \text{HB} \langle / \text{sc} \rangle \text{eAg}$ -positive hepatitis B with sequential treatment failure of lamivudine and adefovir. <i>Liver International</i> , 2012, 32, 1179-1185.	1.9	8
257	A Novel Estimation of the Relative Economic Value in Terms of Different Chronic Hepatitis B Treatment Options. <i>PLoS ONE</i> , 2013, 8, e57900.	1.1	8
258	Spontaneous Neoplastic Remission of Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2015, 65, 312.	0.2	8
259	Prediction of virologic response to tenofovir mono- $\epsilon$ rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1027-1034.	2.5	8
260	An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys). <i>Medicine (United States)</i> 2014;93(10):e44.	0.4	8
261	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , 2017, 11, 292-299.	1.9	8
262	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
263	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363.	1.1	8
264	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
265	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553.	1.0	8
266	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	1.7	8
267	Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA $\geq 2,000$ IU/mL. <i>American Journal of Gastroenterology</i> , 2022, 117, 288-294.	0.2	8
268	A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone. <i>The Korean Journal of Hepatology</i> , 2012, 18, 89.	1.5	8
269	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , 2019, 51, 1347-1356.	1.3	8
270	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2018, 12, 190-200.	1.4	8



#	ARTICLE	IF	CITATIONS
271	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330.	1.4	8
272	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
273	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396.	1.7	8
274	Association Between Polymorphism of Tumor Necrosis Factor- $\beta$ Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2043-2048.	1.1	7
275	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2636-2643.	1.1	7
276	Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. <i>Hepatology Research</i> , 2015, 45, 1331-1340.	1.8	7
277	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431.	1.1	7
278	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	1.4	7
279	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 177-186.	1.4	7
280	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502.	2.5	7
281	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	1.1	7
282	A multicentre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358.	1.0	7
283	Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology International</i> , 2022, 42, 291-302.	1.5	7
284	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	0.8	7
285	When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. <i>World Journal of Gastroenterology</i> , 2014, 20, 7207.	1.4	7
286	Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296.	1.0	7
287	Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). <i>Cancers</i> , 2022, 14, 2733.	1.7	7
288	Clinical Factors Associated with Hepatitis A Virus Seropositivity in HIV-Infected Adults Living in a Country with an Epidemiologic Shift for Hepatitis A Virus Infection. <i>Journal of Korean Medical Science</i> , 2012, 27, 969.	1.1	6

#	ARTICLE	IF	CITATIONS
289	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013, 19, 7671.	1.4	6
290	Prognostic Indicators for Acute Liver Failure Development and Mortality in Patients with Hepatitis A: Consecutive Case Analysis. <i>Yonsei Medical Journal</i> , 2014, 55, 953.	0.9	6
291	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582.	0.9	6
292	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345.	0.4	6
293	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	1.0	6
294	High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1119-1126.	1.0	6
295	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
296	External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958.	1.0	6
297	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	1.8	6
298	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	1.1	6
299	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
300	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	1.7	6
301	Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1023-1025.	1.4	5
302	The Use of Health Functional Foods in Gastrointestinal Cancer Patients. <i>Clinical Nutrition Research</i> , 2013, 2, 19.	0.5	5
303	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.1	5
304	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.4	5
305	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90.	2.5	5
306	HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. <i>Rheumatology International</i> , 2018, 38, 1531-1538.	1.5	5

#	ARTICLE	IF	CITATIONS
307	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	1.8	5
308	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	1.4	5
309	Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2427-2433.	0.9	5
310	Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207.	1.4	5
311	Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 108-116.	0.3	5
312	Genetic risk factors associated with NAFLD. <i>Hepatoma Research</i> , 0, 2020, .	0.6	5
313	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	1.4	5
314	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214.	1.4	5
315	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74.	0.4	5
316	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 144-148.	1.5	4
317	Predictors of Refractory Ascites Development in Patients with Hepatitis B Virus-Related Cirrhosis Hospitalized to Control Ascitic Decompensation. <i>Yonsei Medical Journal</i> , 2013, 54, 145.	0.9	4
318	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	1.6	4
319	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	1.9	4
320	HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. <i>Journal of Cancer</i> , 2020, 11, 2442-2452.	1.2	4
321	Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. <i>Journal of Viral Hepatitis</i> , 2020, 27, 818-825.	1.0	4
322	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
323	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	4
324	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	0.8	4

#	ARTICLE	IF	CITATIONS
325	Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 352-363.	4.5	4
326	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	1.7	4
327	Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 522-524.	0.7	3
328	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
329	Impaired antibacterial response of liver sinusoidal CD39+CD2+ T cells in patients with chronic liver disease. <i>Gut</i> , 2021, , gutjnl-2020-322182.	6.1	3
330	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	1.2	3
331	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105.	1.1	3
332	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3
333	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. <i>Digestion</i> , 2012, 86, 264-272.	1.2	2
334	Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Digestion</i> , 2013, 87, 196-203.	1.2	2
335	Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. <i>Liver International</i> , 2015, 35, 2370-2383.	1.9	2
336	Factors that affect visibility during endoscopic hemostasis for upper GI bleeding: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1392-1400.	0.5	2
337	A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 865-871.	1.4	2
338	New Concept of Hepatocellular Carcinoma Treatment with the Tumor Suppressor WDR76 through RAS Degradation. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 73, 190.	0.2	2
339	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544.	0.8	2
340	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	0.8	2
341	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2757-2766.	1.1	2
342	Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977.	0.9	2

#	ARTICLE	IF	CITATIONS
343	A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75.	0.3	2
344	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
345	Autoimmune Hepatic Failure Following Acute Hepatitis A is Accompanied by Inflammatory Conversion of Regulatory T Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 100.	0.9	2
346	Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 399.	4.5	2
347	Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma. <i>Investigative Magnetic Resonance Imaging</i> , 2019, 23, 351.	0.2	2
348	Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 2317-2326.	1.9	2
349	Hepatic Angiomyolipoma Mimicking Primary Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2016, 68, 284.	0.2	1
350	Histologic Risk Factor for Mortality and Development of Severe Liver Disease in Biopsy-proven Non-alcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2018, 71, 58.	0.2	1
351	Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1306-1318.	1.0	1
352	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	0.6	1
353	Predictors of Sarcopenia in an Obese Asian Population. <i>Nutrition and Cancer</i> , 2022, 74, 505-514.	0.9	1
354	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
355	Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure. <i>Journal of Liver Cancer</i> , 2020, 20, 72-77.	0.3	1
356	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	1.7	1
357	Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. <i>Diagnostics</i> , 2022, 12, 441.	1.3	1
358	Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 26-31.	0.4	1
359	Strategy for Hepatitis C Treatment in Liver Transplant Settings. <i>The Journal of the Korean Society for Transplantation</i> , 2016, 30, 149.	0.2	0
360	Reply to Huang et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 1478-1479.	0.2	0

#	ARTICLE	IF	CITATIONS
361	IDDF2018-ABS-0028â€¦Risk assessment in patients treated with tace due to recurred hepatocellular carcinoma after curative resection. , 2018, , .		0
362	IDDF2018-ABS-0027â€¦Influence of hepatic steatosis on the treatment outcomes of entecavir and tenofovir in patients with chronic hepatitis B. , 2018, , .		0
363	Malignant Transformation of Inflammatory Hepatocellular Adenoma into Hepatocellular Carcinoma. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2018, 72, 267.	0.2	0
364	Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy. Future Virology, 2018, 13, 711-717.	0.9	0
365	Liver transplantation for acute on chronic liver disease; when and how?. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, S8-S8.	0.1	0
366	Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 78, 69-71.	0.2	0
367	A Delayed Hepatico-colonic Fistula after Radiofrequency Ablation in Hepatocellular Carcinoma. Korean Journal of Medicine, 2014, 86, 722.	0.1	0
368	Multiple Hepatic Angiomyolipoma Detected by Abdominal Ultrasonography. Journal of Clinical Ultrasound, 2018, 3, 20-23.	0.0	0
369	Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2020, 75, 308-310.	0.2	0
370	Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 4788-4806.	1.4	0